Navarixin

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameNavarixin
Drug Alias Namenavarixina那伐利星navarixinum那伐立辛navarixine +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonistsC-X-C motif chemokine receptor 1 antagonists
TargetsC-X-C motif chemokine receptor 1C-X-C motif chemokine receptor 2
Therapy Area/IndicationsSolid tumoursPsoriasisPulmonary Disease, Chronic Obstructive +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsSolid tumoursPsoriasisPulmonary Disease, Chronic Obstructive +[7] 

Other Information

ATC CodeN/A
Related LinksKEGG